Outlook Therapeutics Eye Drug Review Returns To FDA — Again - Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.

Raccontata dabenzinga.com